AOD-9604

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic fragment of human growth hormone comprising amino acids 177–191 (the C-terminal fat-metabolizing segment). It was designed to isolate HGH's fat-burning properties without its growth-promoting or diabetogenic effects. Originally developed at Monash University, it stimulates lipolysis and inhibits lipogenesis.

Mimics the lipolytic action of HGH's C-terminal fragment by stimulating beta-3 adrenergic receptor-mediated lipolysis in adipose tissue and inhibiting lipogenesis. Does not bind GH receptors, so it does not increase IGF-1, blood glucose, or promote acromegalic-type growth. Recent research shows cartilage-protective effects, leading to a pivot toward osteoarthritis treatment.

Very short plasma half-life of approximately 30 minutes. Rapidly distributed to adipose tissue. Fat metabolism effects accumulate with repeated dosing over weeks. Typical dose: 300 mcg subcutaneous daily (abdominal injection preferred for local fat effects).

Fat loss without GH side effects, osteoarthritis (cartilage regeneration — pivoted indication), metabolic syndrome, body composition optimization.

Phase 2 obesity trials completed (Metabolic Pharmaceuticals) — failed primary endpoint. Pivoted to osteoarthritis (Calzada Biosciences). FDA IND for intra-articular OA injection. Available off-label through compounding pharmacies for body composition. GRAS status obtained for oral food-grade form in Australia.

• AOD-9604 anti-obesity mechanism — J. Endocrinology · doi.org
• HGH fragment 176-191 lipolytic effects · pubmed.ncbi.nlm.nih.gov
• AOD-9604 cartilage regeneration — Osteoarthritis and Cartilage · pubmed.ncbi.nlm.nih.gov
• AOD-9604 oral bioavailability study · doi.org